NUGX logo

NuGenerex Immuno-Oncology OTCPK:NUGX Stock Report

Last Price

US$0.0001

Market Cap

US$10.1k

7D

0%

1Y

9,900.0%

Updated

24 May, 2023

Data

Company Financials

NuGenerex Immuno-Oncology, Inc.

OTCPK:NUGX Stock Report

Market Cap: US$10.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NUGX Stock Overview

NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer.

NUGX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

NuGenerex Immuno-Oncology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NuGenerex Immuno-Oncology
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$0.30
52 Week LowUS$0.000001
Beta0
11 Month Change0%
3 Month Changen/a
1 Year Change9,900.00%
33 Year Changen/a
5 Year Changen/a
Change since IPO-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

NUGXUS PharmaceuticalsUS Market
7D0%-3.7%-1.6%
1Y9,900.0%17.2%30.8%

Return vs Industry: NUGX exceeded the US Pharmaceuticals industry which returned -1.7% over the past year.

Return vs Market: NUGX exceeded the US Market which returned 4% over the past year.

Price Volatility

Is NUGX's price volatile compared to industry and market?
NUGX volatility
NUGX Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: NUGX's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine NUGX's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993n/aJoe Moscatowww.generex.com/nugenerex-family-of-companies

NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer.

NuGenerex Immuno-Oncology, Inc. Fundamentals Summary

How do NuGenerex Immuno-Oncology's earnings and revenue compare to its market cap?
NUGX fundamental statistics
Market capUS$10.12k
Earnings (TTM)-US$6.29m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NUGX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$6.29m
Earnings-US$6.29m

Last Reported Earnings

Apr 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did NUGX perform over the long term?

See historical performance and comparison